Starting or Strengthening a Drug Bulletin - A Practical Manual
(2005; 165 pages) View the PDF document
Table of Contents
View the documentPreface
View the documentHow the manual was produced
View the documentAbout ISDB
View the documentExecutive summary
Open this folder and view contents1. Introduction
Open this folder and view contents2. Rational use of medicines
Open this folder and view contents3. What are drug bulletins?
Open this folder and view contents4. Defining aims, target and type of bulletin
Open this folder and view contents5. Planning resources
Open this folder and view contents6. Planning bulletin production: schedules and timing
Close this folder7. The editorial process
View the document7.1 Outline of the editorial process
Open this folder and view contents7.2 Editing a drug bulletin
Open this folder and view contents7.3 Writing bulletin articles
Open this folder and view contents7.4 Reviewing the article
View the document7.5. Rewriting the article
View the document7.6 Final checks
Close this folder7.7 Follow-up after publication
View the document7.7.1 Indexing
View the document7.7.2 Authors’ certificates
View the document7.7.3 Post-publication correspondence
View the document7.7.4 Corrections
View the document7.7.5 Requests for reproduction
View the document7.7.6 Keeping track of how bulletin articles are quoted and used
View the document7.8 References
Open this folder and view contents8. Reviewing a new drug: is it a therapeutic advance?
Open this folder and view contentsAnnexe to Chapter 8: Evaluating harm
Open this folder and view contents9. Design and production
Open this folder and view contents10. Dissemination
Open this folder and view contents11. Organizational and legal issues
Open this folder and view contents12. Evaluating quality and usefulness
Open this folder and view contents13. Partnership and collaboration
Open this folder and view contents14. Keeping records and creating a memory
Open this folder and view contentsAppendix: Electronic sources of information
 

7.7.3 Post-publication correspondence

Readers often write to a bulletin, either to express their opinion or discuss technical issues. A bulletin may include a regular section with letters to the editor. Readers often welcome this approach. Even if you do not publish readers’ letters, for example, if your bulletin is too short to have the available space, you will need to reply to readers’ letters.

You may also receive letters of protest, for example from the drug industry and from opinion leaders close to the industry. Some bulletins make these letters public, together with the answers of the editorial team (e.g. la revue Prescrire on its web site: http://www.prescrire.org/) in order to stress the importance of transparency in scientific matters. Sometimes regulatory authorities also write when their decisions have been discussed in articles. In rare cases, bulletins have had legal action started against them (see Chapter 11). The editorial team should be prepared for these sorts of situations.

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: August 29, 2014